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Both overweight and obesity have been identified as risk factors for sexual dysfunction in men, but
the relationship between sexual function and amount of body fat in females is still obscure. There
are few reported studies in women assessing the relationship between female sexual function index
(FSFI) and body weight. The aim of this study was to identify the frequency of female sexual
dysfunction (FSD) among obese and overweight women. A total of 45 obese and overweight
and 30 age-matched voluntary healthy women serving as a control group were evaluated by a
detailed medical and sexual history, including the FSFI questionnaire. Serum prolactin, cortisol,
luteinizing hormone (LH), follicle-stimulating hormone (FSH), dehydroepiandrosterone-SO4
(DHEA-S), testosterone, estradiol and sex hormone-binding globulin (SHBG) levels were measured.
No significant difference was observed between controls and patients in terms of the FSH, LH,
estradiol, free thyroxine and thyrotropin (TSH), testosterone and DHEA-S levels. The comparison of
total FSFI scores between patients and controls showed no significant difference (P¼ 0.74). As the
FSFI score of p26.55 indicated FSD, 86% of obese patients and 83% of controls were considered to
have sexual dysfunction. The mean total FSFI score was 22.1±4.3 for obese patients and 23.1±3.7
for healthy women. FSFI scores were not correlated with any of the anthropometric measurements
(body mass index (BMI), waist-to-hip ratio (WHR) and fat percent). The levels of total testosterone
and DHEA-S were not correlated with total FSFI scores. We found a significant negative correlation
between BMI and orgasm (P¼ 0.007, r¼0.413). Satisfaction was also negatively correlated with
BMI (P¼ 0.05, r¼0.305) and weight (P¼ 0.03, r¼0.326). Testosterone levels were negatively
correlated with only satisfaction domain scores of FSFI (P¼ 0.01, r¼0.385). We found that 86% of
obese women and 83% of controls had sexual dysfunction. Although obesity does not seem to be a
major contributor to sexual dysfunction, it affects several aspects of sexuality.
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Introduction
The increasing prevalence of obesity represents a
major public health problem, with an effect on
physical and emotional well-being and psychosocial
function.1,2 Obesity is on the rise worldwide; bet-
ween 1985 and 2001, the prevalence rates of obesity
have trebled in the United States. More than 30% of
adults in some of the states are now obese.3 In the
2003–2004 time period, the prevalence of obesity
among adults was 32.2%.4
Increasing trends in obesity cause concern among
health authorities in terms of associated co-morbid-
ities, including type II diabetes, heart disease,
hypertension and certain cancer types. Furthermore,
obesity is related with reduced life expectancy and
an increased economic burden to the society.
Somatic and psychological dysfunctions, such as
infertility, osteoarthritis, social disabilities caused by
stigmatization, sleeping problems or apnea, are also
known to follow obesity. Sexual dysfunction may
also be related to obesity, but is rarely mentioned, and
may cause concern for the affected individual and
partner, constituting a great problem.5
The definition of female sexual dysfunction (FSD)
includes persistent or recurrent disorders of sexual
interest/desire, disorders of subjective and genital
arousal, orgasmic disorders and pain and diffi-
culty with attempted or incomplete intercourse.6
The lack of more specific measurable characteristics
in the medical diagnosis of FSD affects the level of
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evidence from clinical trials. Although some studies
suggest that women are more frequently affected
than men, only few clinical trials are available.7
Sexual difficulties in women, influenced by both
health-related and psychosocial factors, seem to be
widespread in society, and are associated with
impaired quality of life and interpersonal relation-
ships.8
Both overweight and obesity have been identified
as risk factors for sexual dysfunction in men,9 but
the relationship between sexual function and
amount of body fat in females is still obscure.10,11
Larsen et al.12 have identified one cross-sectional
study that investigated the association between
obesity and female sexual satisfaction in their
review. Borges et al.13 also stated that the complex-
ity of female sexuality, the lack of well-designed
epidemiological studies and the use of different
tools to assess FSD limit interpretation of results and
conclusions in this area.
The discrepancy among the few reports may
mainly be attributed to the different instruments
used to assess sexual function in women. The
female sexual function index (FSFI) is a brief,
validated, 19-item self-report instrument used in
the assessment of specific sexual dysfunction
symptoms.14 This clinical tool is standardized, easy
to administer and score and provides normal values
in general and pathological populations.15
The relationship between obesity and FSD has
been investigated rarely, and no prospective studies
have been reported on this topic. There is clearly
a need for more studies with prospective data, on
the development of FSD both before and after the
menopause. However, until such studies are per-
formed, the association between obesity and devel-
opment of FSD will remain elusive.
The aim of this study, therefore, was to identify
the frequency of FSD among obese and overweight
women.
Materials and methods
Women seeking weight loss at the Endocrinology
and Metabolism outpatient clinic of Pamukkale
University were screened during a 6-month period.
The study was conducted on 45 otherwise-healthy
obese and overweight women.
As personal sexual habits were questioned,
married women were included in the study, by the
assumption that they could talk more comfortably
on these subjects. Premenopausal women with
regular menstrual cycles, with a body mass index
(BMI) of X25 kgm–2 were included. All subjects met
the requirement of having sexual intercourse at least
once a month. Women were excluded if they were
pregnant, o8 weeks post partum or if they had
experienced any of the following: diabetes mellitus
(fasting glucose X126mg per 100ml on two differ-
ent occasions), impaired glucose tolerance (glucose
levels of 140–200mg per 100ml 2h after a 75-g oral
glucose load) or impaired fasting blood glucose
(glycemia between 100 and 126mg per 100ml)
uremia, multiple sclerosis, chronic alcoholism
(intake of 500 gweek–1), neoplasms, psychiatric
problems, cardiovascular disease, gynecologic sur-
gery, lower urinary tract symptoms, pelvic trauma,
polycystic ovarian syndrome, abnormal thyroid
function and use of any drugs.
Control subjects were age- and menopausal status-
matched 30 women with a normal BMI from the
same population. The study was approved by the
institutional committee of ethical practice of our
institution, and all women gave informed written
consent.
Assessment of sexual function
FSFI, which is a validated, 19-item self-report
instrument, was used for assessing key dimensions
of female sexual function, as previously described
by Rosen et al.14 A total of six domains were
analyzed. Specific domains analyzed in the FSFI
included sexual desire, arousal, lubrication, orgasm,
satisfaction and pain during sexual intercourse.
Sexual desire was assessed as frequency and level
of sexual desire with two questions. Arousal was
assessed as frequency, and level, confidence and
satisfaction with four questions. Lubrication was
assessed as frequency, difficulty, frequency of
maintaining and difficulty in maintaining with
four questions. Orgasm was assessed as frequency,
difficulty and satisfaction with three questions.
Satisfaction was assessed as the amount of closeness
with partner, sexual relationship and overall sex
life with three questions. Pain was assessed as
pain frequency during vaginal penetration and
pain frequency after vaginal penetration with three
questions. Each domain was scored on a scale of
0 or 1–6, with a higher score indicating better
function. A score was calculated for each of the six
domains, and the total score was obtained by adding
the scores of the six domains. The range of the total
score was 2–36, and a score of p26.55 indicated
sexual dysfunction. The tool was administered
during the early follicular (days 2–5) phase of the
menstrual cycle.
Anthropometric measures and laboratory analyses
Height and weight were recorded with participants
wearing lightweight clothing and no shoes using
a Seca 200 scale (Seca, Hamburg, Germany) with
an attached stadiometer. BMI was calculated as
weight in kg divided by the square of height in
meters (kgm–2). The waist-to-hip ratio (WHR)
was calculated as the waist circumference in cm
divided by the hip circumference in cm. Body fat
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distribution (fat percent) was assessed by multiple
frequency bioelectric impedance measurement
using a portable impedance analyzer (Tanita, Tokyo,
Japan).
Assays for glucose were performed in the bio-
chemistry laboratory of the hospital. Blood was
obtained to determine prolactin, luteinizing hor-
mone (LH), follicle-stimulating hormone (FSH),
dehydroepiandrosterone-SO4 (DHEA-S), testoster-
one, estradiol, free thyroxine and thyrotropin
(TSH), cortisol and sex hormone-binding globulin
(SHBG) in the early follicular phase before 1000 h.
The free testosterone levels were calculated accord-
ing to the Vermeulen formula.16 HOMA-IR (home-
ostasis model assessment of insulin resistance) was
determined in the study and control groups. Insulin
resistance was evaluated according to the Lebovitz
classification using a 2.7 cutoff value.17
Statistical analysis
Data are presented as the means for normally
distributed parameters and presented as the med-
ians for other cases (FSH, LH, estradiol, testosterone,
TSH, SHBG and DHEA-S). A two-tailed, unpaired
Student’s t-test was used for comparison of means
between women with or without FSD. The Mann–
Whitney test was used for non-normally distributed
parameters. A value of Po0.05 was considered
significant.
Results
The clinical and metabolic characteristics of women
participating in the study are shown in Table 1.
Table 2 lists the scores of FSFI domains for obese
and overweight patients.
No significant difference was observed between
patients and controls in terms of total FSFI scores
(P¼ 0.74). As a score of p26.55 indicated FSD, 86%
of obese and overweight patients and 83% of
controls were considered to have sexual dysfunc-
tion. The mean total FSFI score for obese patients
was 22.1±4.3 and the mean total FSFI score for
healthy women was 23.1±3.7.
The FSFI scores were not correlated with any of
the anthropometric measurements (BMI, WHR and
fat percent). In the correlation analysis of total FSFI
scores and androgen hormones, the levels of total
testosterone and DHEA-S showed no correlation
with total FSFI scores. There was also no correlation
between FSFI scores and FBG, insulin, estradiol,
FSH, LH, prolactin, TSH, cortisol and SHBG levels.
We found a significant negative correlation between
BMI and orgasm (P¼ 0.007; r¼0.413). Satisfaction
was also negatively correlated with weight (P¼ 0.03;
r¼0.326).
In correlation analysis evaluating age and andro-
gen hormones, a negative correlation was observed
between age and free testosterone levels (P¼ 0.01;
r¼0.35), whereas a negative correlation was
present between age and DHEA-S levels (P¼ 0.00;
r¼0.5). Although there was no correlation be-
tween testosterone and other parameters, free tes-
tosterone levels were positively correlated with BMI
(P¼ 0.001; r¼ 0.472), WHR (P¼ 0.001; r¼ 0.495),
insulin (P¼ 0.00; r¼ 0.698) and DHEAS (P¼ 0.001;
r¼ 0.529) levels. Testosterone levels were negatively
correlated with the scores of satisfaction domain of
Table 1 Clinical and metabolic characteristics of women







Age (years) 36.5±8 33.3±5.2 NS
BMI (kgm–2) 37.5±9.1 22.4±2.3 0.00
WHR 0.88±0.3 0.77±0.5 0.00




Ins (mIUml–1) 12.7±6.5 4.3±3.5 0.00
HOMA-IR 3.21±1.8 1.1±1.1 0.00
Cortisol (nmol l–1) 402.81±157.26 460.8±168.3 NS
FSH (IU l–1) 6.75±12.5 7±3.2 NS
LH (IU l–1) 4.9±11.4 5.5±3.6 NS
E2 (pmol l–1) 165.6±107.2 198.2±117.8 NS
TSH (IU l–1) 1.7±0.98 1.8±1.1 NS
SHBG (nmol l–1) 34.5±17.8 61.4±29.5 0.00
Free T (nmol l–1) 1.08±0.88 0.9±0.6 NS
DHEA-S (mg per 100ml) 150±85.2 157±90.6 NS
PRL (ngml–1) 12.06±4.6 16.51±4.9 NS
FSFI score 22.1±4.3 23.1±3.7 NS
Abbreviations: BMI, body mass index; DHEA-S, dehydroepian-
drosterone-SO4; E2, estradiol; FSFI, female sexual function index;
FSH, follicle-stimulating hormone; HOMA-IR, homeostasis model
assessment of insulin resistance; LH, luteinizing hormone; NS,
not significant; PRL, prolactin; SHBG, sex hormone-binding
globulin; T, testosterone; TSH, free thyroxine and thyrotropin;
WHR, waist-to-hip ratio.
Data are presented as means for normally distributed parameters
and presented as medians for other cases (FSH, LH, E, T, TSH,
SHBG, and DHEA-S).







FSFI score 22.1±4.3 23.1±4.1 NS
Desire 3.1±0.9 3.3±0.7 NS
Arousal 4.0±1.0 4.1±0.7 NS
Lubrication 4.3±1.2 4.5±1.3 NS
Orgasm 4.0±1.4 4.1±1.3 NS
Satisfaction 4.4±1.3 4.5±1.1 NS
Pain 2.4±1.3 2.5±1.0 NS
Abbreviations: FSFI, female sexual function index; NS, not
significant.
Female sexual dysfunction in obesity
GF Yaylali et al
222
International Journal of Impotence Research
FSFI (P¼ 0.01; r¼0.385). There were negative
correlations between serum SHBG levels and WHR
(P¼ 0.05; r¼0.29) and insulin levels (P¼ 0.001;
r¼0.46). Estrogen was positively correlated with
body weight (P¼ 0.001; r¼ 0.48) and fasting insulin
levels (P¼ 0.007; r¼ 0.41).
Discussion
It is unclear whether obese women have sexual
dysfunctions more often than non-obese women.
Clinical trial data suggest an ambiguous association
between obesity and sexual satisfaction in young
women.18,19 Although some studies indicate that
women with normal weight may be more sexually
active than obese and overweight women, other
studies have stated that the contrary may be true.13
However, weight reduction seems to improve sexual
function in young obese women.20–22 Veronelli
et al.23 reported that obese women had a lower
score in the FSFI questionnaire when compared
with healthy women, and a higher FSFI score was
associated with a healthier anthropometric and
metabolic status. In addition, the FSFI global score
was negatively correlated with the known risk
factors for cardiovascular disease, such as blood pre-
ssure, HbA1c, low-density lipoprotein cholesterol
and TSH, whereas it was positively correlated
with high-density lipoprotein cholesterol.23 In our
study, there was no difference between obese and
overweight women and controls in terms of FSFI
scores. As a score of p26.55 indicated FSD, 86% of
obese patients and 83% of controls were considered
to have sexual dysfunction, suggesting that obesity
itself is not a major determining factor in sexual
dysfunction in women.
The prevalence of FSD in different populations is
variable. In a national probability sample of 1749
women between the ages of 18 and 59 years, Lauman
et al.7 reported the risk of experiencing FSD based
on in-person surveys. They observed an overall rate
for sexual problems among women at 43%.7 Addi-
tional instructive reviews have also been published.
Lewis et al.24 concluded that estimates of the
prevalence of low sexual interest among women
showed high variability, ranging from 17 to 55%
in studies that they reviewed. Hayes et al.25 in
Australia found desire disorder to be the most
prevalent FSD condition with a mean of 64% and
a range of 16–75%.25 In addition, using the Women’s
International Study of Health and Sexuality
(WISHeS) data set, Graziottin26 estimated the pre-
valence of desire arousal, and orgasmic disorders
and observed a significant inter-country variation,
with the highest rates of dysfunction in Germany
and the United Kingdom, and the lowest rates in
Italy and France. Data on arousal and orgasmic
disorders were similar, showing the potential for
considerable intercultural variation. Graziottin26
subsequently went on to review the implications of
these data for clinical assessment, and explored
etiologic differentiation and prognostic implica-
tions.
A study concerning the prevalence of FSD in
Turkish population in the Ankara region reported
that the prevalence of FSD was 53.1% between
31 and 45 years of age. According to the FSFI score,
48.3% of women were observed to have FSD.27
Another group from Turkey investigated the pre-
valence of FSD, and possible risk factors causing
FSD in the Mersin region. The prevalence of FSD
was 25.5% between the ages of 28 and 37 years.28
Kadioglu et al.29 studied FSD in hyperprolactinemic
women. FSD was diagnosed in 22 of 25 patients
with hyperprolactinemia (88%), whereas only 4 of
16 healthy women (25%) had FSD by FSFI. Healthy
Turkish women living in the Istanbul region had a
median total FSFI score of 31.10.29 Another group
investigated sexual function in female patients with
coronary artery disease in Istanbul. The average
FSFI total score was 26.0±4.8 in healthy controls,
and 5 of 15 healthy women (33.3%) had FSD
according to a cutoff value of 25.30 These studies
suggest that the prevalence of FSD in different
regions of Turkey may vary widely. This might be
because of the cultural and traditional differences
in different parts of the country. Personal distress
levels about sexual behavior may be difficult to
estimate. To overcome this drawback and estimate
the prevalence of FSD in the general population,
studies in different regions with larger populations
need to be carried out.
Esposito et al.31 showed that obesity affects
several aspects of sexuality, including arousal,
lubrication, satisfaction and orgasm in healthy
Italian women with FSD who were otherwise
healthy. On the other hand, desire and pain were
not affected by obesity. Central fat distribution, as
evaluated by the WHR, showed no correlation with
the FSFI score, nor with any individual sexual
domains, suggesting that the amount of fat is more
important than its distribution.31 It is noteworthy
that, although not significant, desire has been the
only domain showing a positive relationship with
BMI, supporting the hypothesis that the domains of
women’s sexual function may not represent a linear
progression.31,32 The lack of relationship between
BMI and FSFI in women without FSD (r¼ 0.2;
P¼ 0.09) seems to suggest that obesity may be an
important factor once FSD is manifested. It was
speculated that the increasing number of circulating
factors produced by the fat cell may have a role,33
although specifically focused studied are needed.
Women with severe obesity, particularly those
seeking bariatric surgery, are at considerable risk
of having problems with sexual function.34 Bond
et al.35 found that severely obese women seeking
bariatric surgery are clearly a population with
Female sexual dysfunction in obesity
GF Yaylali et al
223
International Journal of Impotence Research
diminished sexual function, with approximately
60% of participants reporting FSD. Compared with
published norms, bariatric surgery candidates had
FSFI domain scores that were lower than those of
the control group (all P-values o0.0001) but greater
than those of the female sexual arousal disorder
group (all P-values o0.0001), except for desire, for
which the scores were similar.35 In this study, we
did not observe any relationship between total FSFI
scores and any anthropometric measurements. How-
ever, when we evaluated the individual sexual
domains, we found that BMI effects orgasm in a
negative manner.
Esposito et al.9 also investigated the association of
metabolic syndrome and FSD, using the FSFI as
previously. Compared with the control group, the
women who had metabolic syndrome had overall
lower FSFI scores (23.2±5.4 vs 30.1±4.7; Po0.001)
and lower scores on the six individual domains,
all of which except desire were statistically sig-
nificant (Po0.01).9 Ponholzer et al.36 found that MS
in premenopausal women was an independent risk
factor for impaired sexual desire (P¼ 0.03, with an
age-adjusted relative risk of 3.3). Kaneshiro et al.37
showed that sexual behavior differs little among
women with different BMI, with the exception of
overweight and obese women who were more likely
to report ever having male sexual intercourse (92 vs
87%, Po0.001). Shah38 reviewed that one may
theorize that there is an increased prevalence of
FSD in obese patients, but confirmation with further
studies is needed.
Adolfsson et al.18 conducted a study on a Swedish
population of 840 younger women (18–49 years), of
whom 18% were overweight and 6% were obese,
and 426 older women (50–74 years), of whom 32%
were overweight and 11% were obese. There was
no difference in terms of sexual life satisfaction
between the obese and normal-weight women in
both age groups. However, in the younger age group
there was a tendency toward lower sexual satisfac-
tion and sexual desire associated with higher
weights.18
Kolotkin et al.19 examined the effect of weight loss
on quality of life among 37 men and women. Among
women, there was no association between weight
changes and changes in sexual life.19
The studies generally find that surgery (jejunoileal
bypass) for obesity may affect sexual relationships
in a positive manner, but the degree of the effect is
not clear.18,19 The study by Rand et al.20 compared
sexual function among 32 morbidly obese women
and 56 morbidly obese men (445 kg overweight),
aged 36–38 years before and after surgery.20 After
1 year of surgery, 61% (n¼ 88) reported a better sex
life compared with the presurgery condition,
whereas 27% reported no change. In addition,
14 participants (34%) reported an increased interest
in sex, and 56% reported that their partner had
showed more interest in sex.21 Kinzl et al.22 found a
low frequency of sexual activity using 82 semistruc-
tured interviews with morbidly obese women
(average BMI, 42.8 kgm–2). Preoperatively, 44%
were satisfied with their sexual life, but more than
one-half of the obese women had some kind of
sexual problem, such as low sexual desire (11.2%),
sexual avoidance or rare sexual intercourse (23.3%)
and difficulty in engaging in sexual intercourse
because of physical problems (11%). Postopera-
tively (1 year later), 63% stated that they enjoyed
sexual intercourse more than pre-operatively.22
The most important factors that may contribute to
an overall change in sexual function after weight
reduction in obese young women are alteration
of the sex hormones, estrogen and androgen, and
improvement in body image. Estrogen is produced
from cholesterol in the ovaries or by aromatization
of steroids in the adipose tissue. A reduction in fatty
tissue can therefore result in decreased levels of
blood cholesterol, aromatization and estrogen.39
Estrogen levels are likely to decrease after weight
loss, and this may directly influence the domains of
both lubrication and pain, resulting in an increase in
sexual pain. We also found a correlation between
estrogen and body weight, but no correlation was
observed with any of the FSFI domains.
The changes in androgen levels after weight
reduction in regularly menstruating obese women
reported in several studies indicate that SHBG
consistently increases after weight loss, and in turn,
free testosterone decreases.3,40–42 Androgen insuffi-
ciency is associated with hypoactive sexual desire
disorder,43 and androgen, in contrast, can increase
sexual desire, arousal, orgasm and satisfaction.44,45
Weight reduction, therefore, can reduce the score in
each of these domains. In other words, as people get
more obese, they tend to have better satisfaction
in sexual life.
Several limitations of the study should be men-
tioned, including the small sample size, and
recruitment of patients from a university outpatient
clinic and from a small region. Thus, the findings of
this study need to be confirmed in a larger patient
population. Because of the limited sample size, our
data cannot be of epidemiologic relevance and
need to be confirmed in studies of larger size. On
the other hand, our study population consisted of
women who applied to the university hospital. This
may not represent the sexual behavior of the entire
population. In addition, the findings might differ in
different regions; thus, further investigations are
needed to confirm these findings.
Conclusion
In this study we found that 86% of obese and
overweight patients and 83% of controls had FSD.
Although obesity does not seem to be a major
contributor to sexual dysfunction, it affects several
aspects of sexuality. As there are inadequate number
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of studies investigating female sexual function and
obesity, further studies with larger sample size are
necessary.
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